Osel, Inc.
Mountain View, CA
- UEI
- R5DDHN86ANH9
- CAGE
- 4KCX1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 320 Logue Ave, Mountain View, CA 94043, USA
- Website
- oselinc.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Regents Of The University Of California. San Francisco | U01AI186333 | $337,669 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Siolta Therapeutics Inc. | San Carlos, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Unlocked Labs Inc. | Laramie, WY | — |
| Topaz Biosciences, Inc. | Emeryville, CA | — |
| Fzata Inc. | Halethorpe, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vedanta Biosciences, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Osel, Inc. is a biotechnology company headquartered in Mountain View, California, specializing in developing live biotherapeutic products and innovative microbiome-based medical interventions. Registered in the System for Award Management (SAM) since 2006, the company focuses on advanced medical research and product development, particularly in the areas of women's health, infectious disease prevention, and cancer treatment. The organization operates as a for-profit corporate entity and has demonstrated expertise in developing sophisticated biological technologies that target specific medical challenges through genetic and microbial engineering approaches.
Through federal grant awards from agencies like the National Cancer Institute and the National Institute of Allergy and Infectious Diseases, Osel, Inc. has pursued groundbreaking research in several critical areas. The company has been developing novel interventions such as MUCOCEPT-CVN, a genetically enhanced Lactobacillus strain designed to prevent HIV acquisition in women, and GASK7B, a selective bacteriocin inhibitor targeting pathogenic Lactobacillus iners in cervical cancer treatment. These projects involve complex scientific work including genetic modification of bacterial strains, development of live biotherapeutic products, and preclinical research aimed at creating innovative medical solutions. Osel, Inc. has collaborated with prominent research institutions like the University of California, San Francisco (UCSF) on sub-award grants, participating in clinical trials, product development, laboratory analysis, and scientific research across multiple stages of investigation, from initial formulation to potential first-in-human clinical trials.
Quick answers
Is Osel, Inc. registered in SAM.gov?
Yes. Osel, Inc.'s SAM.gov registration is active through March 31, 2027.
What is Osel, Inc.'s most recent federal award?
Osel, Inc.'s most recent federal grant award is Novel antimicrobial approach to treat chemoradiation resistant cervical cancer by selectively inhibiting… (R43CA297979), from National Cancer Institute (NIH), on May 20, 2025.
On GovTribe
See Osel, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors